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Abstract: It is recognized that mycotoxins can cause a variety of adverse health effects in 
animals, including altered gastrointestinal barrier function. It is the aim of the present study 
to determine whether mycotoxin-contaminated diets can alter the oral bioavailability of the 
antibiotics  doxycycline  and  paromomycin  in  pigs,  and  whether  a  mycotoxin  adsorbing 
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agent included into diets interacts with those antibiotics. Experiments were conducted with 
pigs utilizing diets that contained blank feed, mycotoxin-contaminated feed (T-2 toxin or 
deoxynivalenol),  mycotoxin-contaminated  feed  supplemented  with  a  glucomannan 
mycotoxin binder, or blank feed supplemented with mycotoxin binder. Diets with T-2 toxin 
and  binder  or  deoxynivalenol  and  binder  induced  increased  plasma  concentrations  of 
doxycycline administered as single bolus in pigs compared to diets containing blank feed. 
These results suggest that complex interactions may occur between mycotoxins, mycotoxin 
binders,  and  antibiotics  which  could  alter  antibiotic  bioavailability.  This  could  have 
consequences for animal toxicity, withdrawal time for oral antibiotics, or public health. 
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1. Introduction 
Toxigenic fungi may often colonize fodder crops and feed components. Under varied environmental 
conditions  they  can  produce  toxic  secondary  metabolites,  called  mycotoxins.  A  recent  study 
investigated the occurrence of mycotoxins in European feed samples and concluded that 82% of the 
samples were contaminated with mycotoxins [1], indicating that mycotoxins are omnipresent. All farm 
animals can experience a negative impact from a dietary intake of mycotoxins but pigs are one of the 
species which are highly sensitive. The economic impact of mycotoxins includes increased mortality, 
increased  veterinary  care  costs,  reduced  livestock  production,  disposal  of  contaminated  foods  and 
feeds and investment in research and applications to reduce the mycotoxin problem [2]. 
Since the gastrointestinal epithelium is the first barrier exposed to mycotoxins after ingestion of 
contaminated feed, research has focused on the effects on barrier integrity. In vitro research revealed 
that mycotoxins are able to increase the permeability of intestinal epithelial cell monolayers. Indeed, 
deoxynivalenol  (DON),  ochratoxin  A  (OTA)  and  patulin  (PAT)  compromise  the  intestinal  barrier 
function  by  altering  the  tight  junction  complex  [3–8].  This  reduced  expression  of  tight  junction 
proteins leads to an increased passage of tracers such as fluorescein isothiocyanate (FITC)-dextran and 
bacteria such as Escherichia coli [9]. In addition, in vivo experiments provide compelling evidence that 
mycotoxins can alter intestinal functions and lead to malabsorption of nutrients like glucose [10,11]. 
To minimize exposure to mycotoxins, a variety of physical, chemical and biological methods has 
been developed in order to eliminate fungi and their mycotoxins from foods and feeds [12,13]. One of 
the most prominent post-harvest strategies is the use of mycotoxin adsorbents as feed additives. By 
including various mycotoxin adsorbing agents in the compound feed, the bioavailability of mycotoxins 
can decrease by reducing their uptake [14].  
The extensive use of adsorbents in the livestock industry has led to the introduction of a wide range 
of new products, most of them offering high in vitro mycotoxin adsorption capacity. Regarding the use 
of these products as feed additives, a primary concern is that the  in vivo efficacy in sequestering 
mycotoxins and the safety towards livestock of most of these commercial products have not yet been 
thoroughly tested [15].  Toxins 2012, 4  283 
 
 
The  European  Commission  [16]  recently  defined  a  new  functional  group  of  feed  additives  as 
“substances for reduction of the contamination of feed by mycotoxins: substances that can suppress or 
reduce the absorption, promote the excretion or modify their mode of action” and requested technical 
advice  from  the  European  Food  Safety  Authority  (EFSA)  on  the  guidelines  to  be  followed  for 
authorization  of  these  additives.  EFSA  stated  that  not  only  in  vitro  but  also  in  vivo  studies  are  
required for the assessment of mycotoxin binders with regard to efficacy testing. A major risk for 
mycotoxin  binders,  however,  is  the  lack  of  selectivity  with  possible  consequences  for  nutritional 
aspects through interactions with dietary compounds. EFSA also reported that one of the parameters to 
be studied is the possible interactions of mycotoxin binders with veterinary medicinal products [17]. 
Additives that exert their activity mainly by binding, may affect the oral bioavailability of drugs.  
To  our  knowledge,  only  a  few  studies  deal  with  this  topic.  [18]  described  a  significantly  lower 
maximal  plasma  concentration  for  lincomycin  in  broilers  after  pretreatment  with  a  mycotoxin  
binder  (Cmax  =  3.27  ±   0.15  µ g· mL
−1),  compared  to  broilers  receiving  no  binder  in  the  feed  
(Cmax = 10.65 ±  0.17 µg· mL
−1). The Bureau of Veterinary Drugs of Canada [19] reported a lack of 
efficacy of tylosin in cattle after intake of a clay containing bentonite which binds tylosin and makes it 
unavailable to the animal. Shryock et al. [20] demonstrated that bentonite (2%), mixed in the feed, 
renders tilmicosin completely ineffective in broiler chickens. This resulted in the prohibition of the use 
of a bentonite feed additive in combination with antibiotics, growth promoters, coccidiostats and other 
medical substances [21].  
Since there are no other scientific papers that investigate these possible interactions, the general aim 
of this study was to examine whether mycotoxins, a commercially available mycotoxin binder, or the 
combination of both in the feed, affect the oral bioavailability of frequently used antibiotics in pigs.  
It  is  generally  accepted  that,  in  the  northern  hemisphere,  Fusarium  moulds  are  among  the  most 
important toxigenic fungi involved in the animal feed chain [22]. Therefore the mycotoxins studied were 
T-2 toxin (T-2) and deoxynivalenol (DON). T-2 is the most potent and cytotoxic trichothecene [23]. 
Moreover it is an emerging Fusarium mycotoxin, for which there are no recommended maximum levels 
in animal feed available yet [24]. DON on the other hand, is one of the most frequent contaminants of 
maize and small grain cereals [25]. Both mycotoxins have already been proven in our laboratory to 
influence the passage of the antibiotics doxycycline and paromomycin across an intestinal epithelial 
monolayer of porcine origin (unpublished results). These antibiotics were also used in this in vivo 
experiment as it is a common practice in current pig husbandry to administer these veterinary drugs by 
„mass‟ medication in feed and/or drinking water.  
2. Materials and Methods 
2.1. Animals 
Twenty-four clinically healthy 9-week-old pigs (Pié train ×  Landrace, local commercial pig farm), 
with a mean (±  SD) body weight of 22.6 ±  1.1 kg, were used in the T-2 experiment (experiment 1). 
The animals were randomized into a control group (n = 6) and three experimental groups (each n = 6).  Toxins 2012, 4  284 
 
 
A second experiment with DON was performed with another twenty-four pigs (Pié train ×  Landrace), 
with a mean (± SD) body weight of 23.1 ±  1.4 kg. The animals were also randomized into a control 
group (n = 6) and three experimental groups (each n = 6). 
All the animals were weighed daily and fed, once a day, 1.5 kg of the assigned feed during the first 
week and 2 kg of the assigned feed during the last two weeks of the experiment. Water was available 
ad libitum. The animals were housed in groups under natural light conditions. 
All animal experiments have been approved by the ethics committee of the Faculty of Veterinary 
Medicine, Ghent University (EC 2009/094 + expansion EC 2010/012 and expansion EC 2010/038 + 
EC2010/120). 
2.2. Feed 
2.2.1. Experiment 1: Influence of T-2 and Mycotoxin Binder on the Oral Absorption of Doxycycline 
and Paromomycin 
Conventional pig feed was purchased (ILVO, Melle, Belgium) and analysed for the presence of 
mycotoxins.  Analysis  with  liquid  chromatography  tandem  mass  spectrometry  (LC-MS/MS)  [1] 
revealed that the feed contained 479 ±  140 µ g· kg
−1 DON and 44 ±  13 µ g· kg
−1 zearalenone. All other 
mycotoxins (n = 21) tested were below the limit of detection (LOD). Since the feed did not contain T-2 
toxin, it was accepted for use in experiment 1. This feed is further referred to as blank feed and was 
used to feed the animals during the acclimatization period as well as to prepare the T-2 contaminated 
feed needed for the experiment. 
To produce feed contaminated with 100 µ g T-2 kg
−1, a stock solution of 250 µ g· mL
−1 T-2 toxin was 
prepared by dissolving 50 mg T-2 (Sigma-Aldrich, Bornem, Belgium) in 200.0 mL ethanol (Merck, 
Darmstadt, Germany). The contaminated feed was produced by adding 120 mL of the stock solution to 
500 g of blank feed. This premix was then mixed with 5 kg of blank feed to assure a homogeneous 
distribution of the toxin. The final premix was then mixed for 20 min in the total amount of feed  
(300 kg) needed for the experiment. To test T-2 toxin homogeneity in the feed, a sample was taken at 
three different locations in the batch and analysed with LC-MS/MS to determine the concentration of 
T-2 toxin. A mean concentration of 99 ±  13 µ g· kg
−1 T-2 was found in this T-2 contaminated feed.  
The binder used in the experiment was a commercially available glucomannan mycotoxin binder 
which claimed to bind T-2 and DON, added at a concentration of 2 kg per metric ton. To produce the 
binder supplemented feed (150 kg), binder was added to both blank feed and feed contaminated with 
100 µ g T-2 kg
−1 feed and mixed for 20 min. A mean concentration of 111 ±  4 µg · kg
−1 T-2 was found 
in this T-2 contaminated feed supplemented with binder. 
2.2.2. Experiment 2: Influence of DON and Mycotoxin Binder on the Oral Absorption of Doxycycline 
and Paromomycin 
Conventional feed was purchased (DANIS, Koolskamp, Belgium) and analysed with LC-MS/MS 
for the presence of mycotoxins. As the feed only contained 11 ±  4 µ g· kg
−1 T-2 and no other mycotoxins 
such as DON, the feed was used to feed the animals during the acclimatization period as well as to 
prepare  the  DON  contaminated  feed  needed  for  the  experiment.  The  reference  strain  Fusarium Toxins 2012, 4  285 
 
 
graminearum MUCL 42841 (Mycothè que de l‟Université catholique de Louvain) was used to produce 
DON, for inclusion in feed at a theoretical concentration of 1 mg· kg
−1. The strain was grown in liquid 
mineral medium supplemented with L-arginin as a selective nitrogen source [26]. After 14 days of 
cultivation, the culture was filtered and centrifuged. The supernatant was freeze-dried and mixed into 
the blank feed (300 kg) until a final DON concentration of 1 mg· kg
−1 was obtained. To test DON 
homogeneity in the feed, a sample was taken at three different locations in the batch and analysed with 
LC-MS/MS to determine the concentration of DON. A mean concentration of 802 ±  23 µg · kg
−1 DON 
was found and the feed was accepted to be used in the experiment. Blank feed supplemented with 
binder (150 kg) was produced as described in experiment 1. A mean concentration of 813 ±  24 µg · kg
−1 
DON was found in this DON contaminated feed supplemented with binder. 
2.3. Study Design 
2.3.1. Experiment 1 
After an acclimatization period of one week, during which all animals received blank feed, the four 
groups of six animals received blank feed (control), feed contaminated with 99 ±  13 µ g T-2 kg
−1 feed, 
feed contaminated with 111 ±  4 µ g T-2 kg
−1 feed and supplemented with the mycotoxin binder or 
blank feed supplemented with the mycotoxin binder, respectively.  
After  the  intake  of  the  experimental  diet  for  seven  days,  the  animals  received  a  single  oral 
intragastric bolus of doxycycline (Soludox 50%
®, Eurovet, Bladel, The Netherlands) and paromomycin 
(Gabbrovet  70
®,  CEVA  Santé   Animale,  Brussels,  Belgium).  The  oral  solution  was  prepared  by 
dissolving the powders in tap water. Doxycycline was given at a dose of 10 mg· kg
−1 body weight and 
paromomycin  at  100  mg· kg
−1  body  weight.  Blood  samples  were  collected  in  heparinised  tubes 
(Venoject
®, Terumo Corp., Tokyo, Japan) by puncturing the external jugular vein with a 20 G needle 
(20 G, 0.9 ×  38 mm, Terumo Corp., Tokyo, Japan) before and at 0.5, 1, 2, 3, 4, 6, 8, 12 and 24 h after 
administration. The samples were centrifuged at 2,851 g at 4 ° C for 10 min and plasma was stored at 
−15 ° C until assayed for paromomycin and doxycycline.  
2.3.2. Experiment 2 
To evaluate whether another trichothecene mycotoxin results in findings comparable to the first 
experiment, a second experiment was performed using the mycotoxin DON. After an acclimatization 
period of one week, four groups of six animals received for 13 days respectively blank feed (control), 
feed contaminated with 802 ±  23 µg· kg
−1 DON, feed contaminated with 813 ±  24 µ g· kg
−1 DON and 
supplemented with the mycotoxin binder and blank feed supplemented with the mycotoxin binder. 
Subsequently  the  animals  received  a  single  oral  bolus  of  doxycycline  (10  mg· kg
−1  BW)  and 
paromomycin (100 mg· kg
−1 BW), blood was drawn and plasma samples were collected as described in 
experiment 1. 
2.4. Doxycycline Determination in Plasma  
Plasma  doxycycline  concentration  was  determined  by  high-performance  liquid  chromatography 
(HPLC), using ultraviolet detection, based on the procedure described by Baert et al. [27].  Toxins 2012, 4  286 
 
 
The  method  was  in-house  validated  by  a  set  of  parameters  that  were  in  compliance  with  the 
recommendations  as  defined  in  several  EU  documents  [28–31].  The  following  parameters  were 
evaluated: linearity, within-run and between-run accuracy and precision, limit of quantification (LOQ), 
limit of detection (LOD), specificity. Quantification was performed using matrix-matched calibration 
curves  (concentration  range:  200–1,000  ng· mL
−1  and  2,000–10,000  ng· mL
−1)  and  the  correlation 
coefficients (r = 0.9963 ±  0.0030, n = 6 and r = 0.9962 ±  0.0030) and goodness-of-fit coefficients  
(g = 5.65 ±  2.49% and 5.37 ±  2.44%, n = 6) fell within the accepted ranges, i.e., r ≥ 0.99 and g ≤ 10%, 
respectively.  The  internal  standard  (IS,  demethylchlortetracycline,  chemical  reference  substance, 
European Pharmacopoeia, Strasbourg, France) was added to all samples prior to the start of the sample 
preparation procedure. Since the principle of internal standardization was used for quantification, no 
correction factor had to be applied for analyte loss during sample preparation (extraction recovery). 
Within-run and between-run precision and accuracy were evaluated by analyzing 6 independently 
spiked samples at 2 concentration levels, i.e., 1000 and 5000 ng· mL
−1, respectively. The following mean 
results were obtained: within-run accuracy (n = 6): 908.0 ±  40.4 ng· mL
−1 and 4955 ±  223.0 ng· mL
−1; 
between-run accuracy (n = 6): 912.0 ±  43.3 ng· mL
−1 and 4,810 ±  153.9 ng· mL
−1. The results fell within 
the accepted ranges for accuracy (−20 to +10% of the theoretical concentration) and precision (within-
run precision: relative standard deviation (RSD) ≤ RSDmax with RSDmax = 2
(1−0.5log Conc) ×  2/3, i.e., 
10.7%  and  8.4%  at  1000  ng· mL
−1  and  5000  ng· mL
−1,  respectively;  between-run  precision: 
RSD ≤ RSDmax with RSDmax = 2
(1−0.5log Conc), i.e., 16.0% and 12.6% at 1,000 ng· mL
−1 and 5,000 ng· mL
−1, 
respectively). The LOQ was defined as the lowest concentration for which the method was validated 
with a within-run accuracy and precision that fell within the specified ranges. The LOQ was also the 
lowest  point  of  the  calibration  curve  and  was  set  at  200  ng· mL
−1  (n  =  6,  mean  result:  
190.2 ±  3.44 ng· mL
−1). The LOD was defined as the concentration corresponding with a signal-to-noise 
ratio of 3 and was found to be 82.6 ng· mL
−1. The specificity of the method was shown, since no peaks 
of endogenous interferences could be determined in blank samples. 
2.5. Paromomycin Determination in Plasma 
The  concentration  of  paromomycin  in  plasma  was  determined  by  LC-MS/MS.  Samples  were 
prepared by pipetting 500 µL plasma into an Eppendorf cup (Novolab, Geraardsbergen, Belgium). 
Each sample was spiked with 50 µ L of the IS (tobramycin, Sigma) working solution of 5 µg · mL
−1 in 
HPLC grade water (VWR International, Leuven, Belgium). After vortexing briefly, 100 µ L of a 20% 
trichloroacetic acid (TCA) solution in water were added to deproteinize. After vortexing for 15 sec, the 
samples were centrifuged at 7,800 g for 10 min. The upper layer was transferred into screw-capped 
polypropylene vials for HPLC and 100 µ L were injected onto the LC-MS/MS system. 
The HPLC system consisted of a quaternary gradient pump type P4000 and an AS3000 autosampler 
coupled to a LCQ
® mass spectrometer with an electrospray ionization source operating in the positive 
ionization mode (ThermoFischer Scientific, Zellik, Belgium). 
Chromatographic  separation  was  achieved  using  a  Nucleosil  column  (100  mm  ×   3  mm  i.d.,  
dp: 5 µ m, Varian) protected with a guard column of the same type (10 mm ×  2 mm i.d., Varian). The 
mobile phase consisted of 20 mmol·L
−1 pentafluoropropionic acid (PFPA) (Sigma-Aldrich) in water 
(A) and 20 mmol· L
−1 PFPA in water/acetonitrile (50/50, v/v) (VWR International) (B). A gradient Toxins 2012, 4  287 
 
 
elution was performed at a flow-rate of 0.2 mL· min
−1, i.e., 0–4 min, 40% B; 4–6 min: linear gradient to 
90% B, 6–6.1 min, linear gradient to 40% B, 6.1–10.5 min, 40% B. Paromomycin and the IS eluted at 
5.45 and 5.68 min, respectively. A divert valve was used to direct the HPLC column effluent to the MS 
system from 4.5 to 7.5 min only, which prevented the MS system from quick contamination. 
The method was in-house validated by the same parameters as for the DOX analysis  [28–31]. 
Quantification  was  performed  using  matrix-matched  calibration  curves  (concentration  range:  
50–5,000 ng· mL
−1) and the correlation coefficients (r = 0.9981 ±  0.0005, n = 6) and goodness-of-fit 
coefficients  (g  =  8.29  ±   1.71%,  n  =  6)  fell  within  the  accepted  ranges,  i.e.,  r  ≥  0.99  and  
g ≤ 10%, respectively.  
Within-run and between-run precision and accuracy were evaluated at 2 concentration levels, i.e., 
250 and 2,500 ng· mL
−1, respectively. The following mean results were obtained: within-run accuracy 
and precision (n = 6): 228.1 ±  11.5 ng· mL
−1 and 2,603 ±  191.8 ng· mL
−1; between-run accuracy and 
precision  (n  =  6):  225.2  ±   15.7  ng· mL
−1  and  2,410  ±   165.8  ng· mL
−1.  The  results  fell  within  the 
accepted  ranges  for  accuracy  (−20  to  +10%  of  the  theoretical  concentration)  and  precision  
(RSD ≤ RSDmax with RSDmax for within-run precision: 13.1% and 9.3% and RSDmax for between-run 
precision: 19.7% and 13.9% at a concentration level of 250 ng· mL
−1 and 2,500 ng· mL
−1, respectively). 
The LOQ was set at 50 ng· mL
−1 (n = 6, mean result: 46.9 ±  5.26 ng· mL
−1), while the LOD was found 
to  be  0.09  ng· mL
−1.  The  specificity  of  the  method  was  shown,  since  no  peaks  of  endogenous 
interferences could be determined in blank samples. 
2.6. Pharmacokinetic and Statistical Analysis 
Plasma  concentration  versus  time  data  were  analyzed  by  means  of  WinNonlin
®,  Version  6.2.0 
(Pharsight  Corporation,  Mountain  View,  CA,  USA)  software  program  using  noncompartmental 
analysis.  The  area  under  the  plasma  concentration-time  curve  from  dosing  to  the  last  measured 
concentration (AUC0–24h) was calculated via the trapezoidal method. Data were statistically analyzed 
using SPSS 17.0 software for Windows (SPSS Inc., Chicago, IL, USA). Normally distributed data 
were analyzed using one-way analysis of variance (ANOVA) to address the significance of difference 
between mean values with significance set at P ≤ 0.05. Bonferroni as post hoc test was used when 
equal variances were assessed. Not normally distributed data were analyzed using the non-parametric 
Kruskal-Wallis analysis, followed by a Dunn‟s Multiple Comparison test. 
3. Results  
3.1. Experiment 1 
3.1.1. Intake of T-2 Contaminated Feed Supplemented with Mycotoxin Binder Results in Significant 
Higher Plasma Concentrations of Doxycycline  
For  the  different  groups,  the  plasma  concentration-time  curve  of  doxycycline  after  oral  (p.o.) 
administration is presented in Figure 1.  Toxins 2012, 4  288 
 
 
Figure 1. Mean plasma concentrations (+SD) in pigs after a single peroral administration 
of doxycycline at 10 mg kg
−1 body weight (n = 6). Prior to the bolus, pigs received during 
7 days, blank feed (control group), feed contaminated with 100 µ g T-2 toxin per kg feed, 
feed contaminated with 100 µ g T-2 toxin per kg feed supplemented with mycotoxin binder 
and blank feed supplemented with mycotoxin binder, respectively. 
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The group which received feed supplemented with 100 µg T -2 kg
−1  feed  and  binder  showed 
significantly higher plasma concentrations compared to the control group (P = 0.033), but not to the 
other experimental groups. The group which received 100 µ g T-2 kg
−1 feed and the one that received 
blank feed supplemented with the mycotoxin binder had plasma concentrations that were not different 
with  the  control  group.  The  mean  area  under  the  plasma  concentration-time  curve  (AUC0–24h)  is 
summarized in Table 1.  
Table  1. Mean (±  SD) area under the plasma concentration-time curve (AUC0–24h) for 
doxycycline in the different groups. Prior to the bolus, pigs received during 7 days, blank 
feed  (control  group),  feed  contaminated  with  100  µ g  T-2  toxin  per  kg  feed,  feed 
contaminated with 100 µ g T-2 toxin per kg feed supplemented with mycotoxin binder and 
blank feed supplemented with mycotoxin binder, respectively. Superscript (*) refers to a 
significant difference compared to the control group (P < 0.05). 
Group  AUC0–24h (ng/mL*h) 
Control (blank feed)  22,653 (± 16,275) 
100 µ g· kg
−1 T-2  29,320 (± 13,334) 
100 µg· kg
−1 T-2 + binder  43,961 (± 7,982) * 
Blank feed + binder  29,343 (± 7,681) 
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3.1.2. Intake of Binder Supplemented Feed Results in Higher Plasma Concentrations of Paromomycin 
The plasma concentration-time curve of paromomycin after p.o. administration for the different 
groups is presented in Figure 2. 
Figure 2. Mean plasma concentrations (+SD) in pigs after single peroral administration of 
paromomycin at 100 mg kg
−1 body weight (n = 6). Prior to the bolus, pigs received during 
7 days, blank feed (control group), feed contaminated with 100 µ g T-2 toxin per kg feed, 
feed contaminated with 100 µ g T-2 toxin per kg feed supplemented with mycotoxin binder 
and blank feed supplemented with mycotoxin binder, respectively. 
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Although a trend for higher plasma concentrations after intake of binder supplemented feed was 
seen, there were no significant differences in plasma concentrations or AUC0–24h of paromomycin on 
the basis of treatment. 
3.2. Experiment 2 
3.2.1. Intake of DON Contaminated Feed Supplemented with Mycotoxin Binder Results in Higher 
Plasma Concentrations of Doxycycline 
The  plasma  concentration-time  curve  for  doxycycline  after  p.o.  administration  is  presented  in 
Figure 3 for the different groups. 
The plasma concentration of doxycycline was significantly (P = 0.045) higher in the group which 
received  DON  contaminated  feed  supplemented  with  the  mycotoxin  binder,  but  not  to  the  other 
experimental groups.  
The mean area under the plasma concentration-time curve (AUC0–24h) is summarized in Table 2. Toxins 2012, 4  290 
 
 
Figure 3. Mean plasma (+SD) concentrations in pigs after single peroral administration of 
doxycycline at 10 mg kg
−1 body weight (n = 6). Prior to the bolus, pigs received during  
13 days, blank feed (control group), feed contaminated with 1 mg DON per kg feed, feed 
contaminated with 1 mg DON per kg feed supplemented with mycotoxin binder and blank 
feed supplemented with mycotoxin binder, respectively. 
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Table  2.  Mean  (± SD)  area  under  the  plasma  concentration-time  curve  (AUC0–24h)  for 
doxycycline in the different groups. Prior to the bolus, pigs received during 13 days, blank 
feed (control group), feed contaminated with 1 mg DON per kg feed, feed contaminated 
with  1  mg  DON  per  kg  feed  supplemented  with  mycotoxin  binder  and  blank  feed 
supplemented with mycotoxin binder, respectively. Superscript (*) refers to a significant 
difference compared to the control group (P < 0.05). 
Group  AUC0–24h (ng/mL*h) 
Control (blank feed)  19,011 (± 2,805) 
1 mg· kg
−1 DON  20,107 (±3,304) 
1 mg· kg
−1 DON + binder  40,029 (±22,775) * 
Blank feed + binder  26,783 (±4,752) 
3.2.2. No Statistical Different Plasma Concentrations of Paromomycin after Intake of DON 
Contaminated Feed 
Plasma concentrations of paromomycin after intake of DON contaminated feed were not significantly 
different compared to the control group (Figure 4). Toxins 2012, 4  291 
 
 
Figure 4. Mean (+SD) plasma concentrations in pigs after single peroral administration of 
paromomycin at 100 mg· kg
−1 body weight (n = 6). Prior to the bolus, pigs received during 
13 days, blank feed (control group), feed contaminated with 1 mg DON per kg feed, feed 
contaminated with 1 mg DON per kg feed supplemented with mycotoxin binder and blank 
feed supplemented with mycotoxin binder, respectively. 
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4. Discussion 
The results obtained indicate that there is a need for extensive research into the field of safety 
testing of mycotoxin detoxifying agents. Indeed, on request of the European Commission, the Panel on 
Additives and Products or Substances used in Animal Feed derived a proposal for the modification of 
Annex  III  of  Commission  Regulation  (EC)  No  429/2008  [32].  For  the  authorization  of  additives 
belonging  to  the  functional  group  of  substances  for  reduction  of  the  contamination  of  feed  by 
mycotoxins,  one  of  the  parameters  that  needs  to  be  taken  into  account  is  the  presence  and 
characterization of possible interactions of the binder with, among others, veterinary medicinal products. 
In  the present  study, the  effect  of mycotoxins and  a  commonly  used  mycotoxin binder on the 
absorption of two frequently used antibiotics in pigs was investigated in vivo. The study was conducted 
in  pigs  because,  among  farm  animals,  pigs  react  most  sensitively  to  exposure  to  trichothecene 
mycotoxins [33]. The antibiotics tested were doxycycline and paromomycin. These veterinary drugs 
are often used in pigs in „mass‟ medication and are frequently administered via the oral route, i.e., 
mixed in the feed or drinking water. The mycotoxins used were the trichothecenes DON and T-2. T-2 
toxin is the most potent and toxic trichothecene for which there are no recommended maximum levels 
in animal feed [24]. The contamination level used in the experiment was based on Monbaliu et al. [1] 
who analyzed 82 feed samples from different European countries for the presence of mycotoxins.  
As T-2 was found at a concentration ranging from 10–122 µ g· kg
−1 it was decided to produce feed 
contaminated with 100 µ g· kg
−1. DON on the other hand is one of the most frequent contaminants of 
maize and small grain cereals with a recommended maximum concentration level of 900 µ g· kg
−1 of 
DON  in  pig  feed  [24].  It  was  decided  to  respect  this  limit  and  work  with  a  concentration  of 
approximately 1,000 µ g· kg
−1. The mycotoxin adsorbing agent used was an esterified yeast cell wall 
that claims to bind DON and T-2. Toxins 2012, 4  292 
 
 
Regarding the plasma concentration of doxycycline, the concentration-time curve of the control 
group shows a profile as described previously [27]. At 6 h post administration two out of six pigs 
showed an extra peak in the plasma concentration-time profile. This may be due to the enterohepatic 
recirculation of doxycycline [34]. Compared to this control group the plasma concentrations were 
significantly higher in the group which received feed contaminated with 100 µ g T-2 kg
−1 supplemented 
with the mycotoxin binder. Remarkably, the AUC was almost double compared to the AUC of the 
control group. Significant higher plasma concentrations of doxycycline were also found when the 
mycotoxin DON was added together with the mycotoxin binder in the feed.  
In  an  attempt  to  clarify the mechanism behind  the increased  plasma  concentrations,  a  possible 
interaction of the binder with divalent ions such as Ca
2+ and Mg
2+, which normally partially bind 
doxycycline [35], was presented as potential explanation. With less bound doxycycline present in the 
intestinal lumen, more doxycycline could then enter the systemic circulation. To check this assumption 
an extra experiment was performed with oxytetracycline as antibiotic. Oxytetracycline also belongs to 
the  class  of  tetracyclines  like  doxycycline  and  binds  even  stronger  to  divalent  ions  [36].  If  our 
assumption was correct, the effects seen with doxycycline should be even  more pronounced with 
oxytetracycline. However, no statistical difference in plasma oxytetracycline concentration could be 
demonstrated between the groups receiving either blank feed or blank feed supplemented with binder. 
In  the  oxytetracycline  experiment  however,  no  T-2  toxin  was  added  to  the  feed.  Therefore,  the 
increased  plasma  concentrations  seen  for  doxycycline  are  probably  the  result  of  a  more  complex 
interaction between mycotoxin, binder and drug.  
For paromomycin, there was no statistical difference in plasma concentrations between the groups. 
This  is  possibly  due  to  the  great  variation  in  plasma  concentration  between  the  individual  pigs. 
Although not significant, there is a tendency that the intake of binder supplemented feed also leads to 
an increased plasma concentration.  
Recent in vivo experiments at our department with broiler chickens also confirm the possible role of 
binders in the absorption of antibiotics. In chickens, increased plasma concentrations of oxytetracycline 
were seen after intake of feed supplemented with a mycotoxin detoxifying agent (unpublished data). 
We  also  showed  that,  in  chickens,  administration  of  a  single  bolus  of  DON  combined  with  a 
glucomannan binder leads to increased plasma concentrations of DON compared to the control group 
which received a bolus with only DON (unpublished data).  
The mechanisms for these phenomena still remain unknown but it demonstrates that effects can be 
binder,  species  and  drug  specific.  Another  possible  explanation  that  we  put  forward  is  that  the 
mycotoxin binder affects the intestinal epithelium in which the duration of exposure can play a role, 
for example by loosening of the tight junctions, stimulating the production of cytokines, influencing 
the length of villi and depth of crypts, influencing the production of mucus etc., which could result in 
increased passage of antibiotics across the intestinal wall. 
In conclusion, our results demonstrate that the studied mycotoxin binder may significantly affect 
the oral bioavailability of doxycycline. This may be of importance for the animal, the withdrawal time 
of  veterinary  drug  formulations  containing  doxycycline,  and  consequently  for  public  health  with 
respect  to  tissue  residues  of  the  antibiotic.  On  the  other  hand,  if  the  mycotoxin  binder  leads  to 
increased plasma concentrations, this can be compensated by reducing the dosage of the antibiotic. Toxins 2012, 4  293 
 
 
However, since the effects depend on the type of detoxifying agent, type  of drug and the animal 
species, further research is needed to elucidate possible interaction mechanisms. 
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